Darovasertib and Crizotinib for HLA-A2-Negative Metastatic Uveal
Darovasertib and Crizotinib for HLA-A2-Negative Metastatic Uveal Melanoma
IDEAYA Biosciences ($IDYA)
Will this trial show a positive result on overall survivalOutcome measureOverall Survival (OS)Overall survival measures how long patients live after treatment starts. It is usually the hardest and most market-important oncology endpoint because it reflects direct patient benefit.ClinicalTrials.gov outcome in Phase 3?
Paper Trading
Create account to trade- Primary Completion
- 1/15/27
- Study Completion
- 1/15/28
- Sponsor
- Ticker
- $IDYA
- Type
- Trial Status
- Active Not Recruiting
- Trial Size
- 420
- NCT
- NCT05987332
- Trial Description
- This trial tests first-line darovasertib plus crizotinib in HLA-A2-negative metastatic uveal melanoma, measuring cancer control and survival.